Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects

Chest

Volumn 128, Issue 1, 2005, Pages 70-77

  Chrousos, George P ^a   Ghaly, Lisa ^b   Shedden, Arthur ^b   Iezzoni, Domenic G ^b   Harris, Alan G ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE

Author keywords

Asthma; Beclomethasone dipropionate; Corticosteroid; Hypothalamo hypophyseal system; Mometasone furoate

Indexed keywords

BECLOMETASONE DIPROPIONATE; CHLOROFLUOROCARBON; FLUORINATED HYDROCARBON; HYDROCORTISONE; MOMETASONE FUROATE; PROPELLANT;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFECT; DRY POWDER; DYSPEPSIA; DYSPHONIA; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PEAK EXPIRATORY FLOW; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SORE THROAT; THROAT DISEASE;

EID: 22244470407     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.1.70     Document Type: Article

References (24)

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. National Institutes of Health, National Heart, Lung and Blood Institute 2002. Available at: www.ginasthma.com. Accessed June 16, 2005
2. Wilson JW, Djukanovic R, Howarth PH, et al. Inhaled beclomethasone dipropionate downregulates airway lymphocyte activation in atopic asthma. Am J Respir Crit Care Med 1994; 149:86-90
3. Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1998; 102:531-538
4. Rutherford C, Mills R, Gibson PG, et al. Improvement in health-related quality of life with fluticasone propionate compared with budesonide or beclomethasone dipropionate in adults with severe asthma. Respirology 2003; 8:371-375
5. Toogood JH. Side effects of inhaled corticosteroids. J Allergy Clin Immunol 1998; 102:705-713
6. Goldberg S, Einot T, Algur N, et al. Adrenal suppression in asthmatic children receiving low-close inhaled budesonide: comparison between dry powder inhaler and pressurized metered-dose inhaler attached to a spacer. Ann Allergy Asthma Immunol 2002; 89:566-571
7. Dempsey OJ, Wilson AM, Contie WJ, et al. Evaluation of the effect of a large volume spacer on the systemic bioactivity of fluticasone propionate metered-dose inhaler. Chest 1999; 116:935-940
8. Kelly HW, Nelson HS. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol 2003; 112:469-478
9. Chrousos GP, Harris AG. Hypothalmic-pituitary-adrenal axis suppression and inhaled corticosteroid therapy: I. General principles. Neuroimmunomodulation 1998; 5:277-287
10. Kemp JP, Berkowitz RB, Miller D, et al. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol 2000; 106:485-492
11. Fish JE, Karpel JP, Craig TJ, et al. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol 2000; 106:852-860
12. Affrime MB, Kosoglu T, Thonoor CM, et al. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high dose. Chest 2000; 118:1538-1546
13. Lipworth BJ, Jackson CM. Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionate. Br J Clin Pharmacol 1999; 48:866-868
14. Lipworth BJ, Jackson CM. Influences on plasma Cortisol of different formulations of beclomethasone dipropionate [letter]. Br J Clin Pharmacol 2000; 50:381
15. Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002; 165:1377-1383
16. Grinspoon K, Biller S. Laboratory assessment of adrenal insufficiency. J Clin Endocrinol Metab 1994; 79:923-931
17. Fink RE, Pierre LN, Daley-Yates PT, et al. Hypothalmic-pituitary-adrenal axis function after inhaled corticosteroids: unreliability of urinary free cortisol estimation. J Clin Endocrinol Metab 2002; 87:4541-4546
18. Wilson AM, Lipworth BJ. 24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids. Thorax 1999; 54:20-26
19. Fowler SJ, Orr LC, Wilson AM, et al. Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate. Br J Clin Pharmacol 2001; 52:93-95
20. Abdu TAM, Elhadd TA, Neary R, et al. Comparison of the low dose short synacthen test (1 microg), the conventional dose short svnacthen test (250 microg), and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease. J Clin Endocrinol Metab 1999; 84:838-843
21. Affrime MB, Cuss F, Padhi D, et al. Bioavailability and metabolism of inometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol 2000; 40:1227-1236
22. Le Souef P. The meaning of lung close. Allergy 1999; 54(suppl):93-96
23. Daley-Yates PT, Tournant J, Kunka RL. Comparison of the systemic availability of fluticasone propionate in healthy volunteers and patients with asthma. Clin Pharmacokinet 2000; 39(suppl):39-45
24. Brutsche MH, Brutsche IC, Munawar M, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000; 356:556-561